108 related articles for article (PubMed ID: 14707990)
1. Diabetic maculopathy and lipid-lowering therapy.
Misra A; Vikram NK; Kumar A
Eye (Lond); 2004 Jan; 18(1):107-8. PubMed ID: 14707990
[No Abstract] [Full Text] [Related]
2. The role of serum lipids in exudative diabetic maculopathy: is there a place for lipid lowering therapy?
Chowdhury TA; Hopkins D; Dodson PM; Vafidis GC
Eye (Lond); 2002 Nov; 16(6):689-93. PubMed ID: 12439660
[TBL] [Abstract][Full Text] [Related]
3. [Statines for all or individualized lipid lowering therapy?].
Parhofer K
MMW Fortschr Med; 2009 Apr; 151(14):100, 102-4; quiz 105. PubMed ID: 19504849
[No Abstract] [Full Text] [Related]
4. Lipid lowering therapy for adults with diabetes.
Jackowski L; Crockett J; Rowett D
Aust Fam Physician; 2008; 37(1-2):39-41. PubMed ID: 18239751
[TBL] [Abstract][Full Text] [Related]
5. Effect of lipid-lowering drug therapy on small-dense low-density lipoprotein.
Backes JM; Gibson CA
Ann Pharmacother; 2005 Mar; 39(3):523-6. PubMed ID: 15671087
[TBL] [Abstract][Full Text] [Related]
6. [Lipid-lowering therapy in chronic kidney disease].
Fernández-Vega F
Nefrologia; 2004; 24 Suppl(6):113-26, 187-235. PubMed ID: 15696902
[No Abstract] [Full Text] [Related]
7. Statin therapy in heart failure.
Soaly E; Al Suwaidi J
Expert Rev Cardiovasc Ther; 2005 Jan; 3(1):5-7. PubMed ID: 15723569
[No Abstract] [Full Text] [Related]
8. [Lipid-lowering cardiovascular prevention in type 2-diabetes. Statins are effective according to the FIELD study].
Båvenholm P; Attvall S; Nilsson PM
Lakartidningen; 2006 Aug 30-Sep 5; 103(35):2462-6. PubMed ID: 17002161
[No Abstract] [Full Text] [Related]
9. [Treatment of dyslipidemia in the secondary prevention of coronary artery disease].
Syvänne M
Duodecim; 1998; 114(15):1503-8. PubMed ID: 11552239
[No Abstract] [Full Text] [Related]
10. Lipids, diabetic maculopathy, and cardiovascular risk.
Gandhi JS
Eye (Lond); 2004 Jan; 18(1):108-9. PubMed ID: 14707991
[No Abstract] [Full Text] [Related]
11. Lipid-lowering therapy and the patient with multiple risk factors: what have we learned from the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT)?
Sever PS
Am J Med; 2005 Dec; 118 Suppl 12A():3-9. PubMed ID: 16356801
[TBL] [Abstract][Full Text] [Related]
12. Rationale for aggressive lipid lowering: evidence from clinical trials.
Farmer JA
Expert Rev Cardiovasc Ther; 2004 May; 2(3):305-9. PubMed ID: 15151477
[No Abstract] [Full Text] [Related]
13. Lipid modification: cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease.
Robson J
Heart; 2008 Oct; 94(10):1331-2. PubMed ID: 18701534
[No Abstract] [Full Text] [Related]
14. Complications and side effects. Crestor tested in PHAs.
TreatmentUpdate; 2005; 17(4):6-7. PubMed ID: 17230630
[No Abstract] [Full Text] [Related]
15. Lipid lowering treatment patterns and goal attainment in Nordic patients with hyperlipidemia.
Svilaas A; Strandberg T; Eriksson M; Hildebrandt P; Westheim A
Scand Cardiovasc J; 2008 Aug; 42(4):279-87. PubMed ID: 18609053
[TBL] [Abstract][Full Text] [Related]
16. Novel approaches to the treatment of dyslipidemia.
Rader DJ
Arterioscler Thromb Vasc Biol; 2005 Mar; 25(3):480-1. PubMed ID: 15731488
[No Abstract] [Full Text] [Related]
17. Combination therapy for the treatment of dyslipidemia.
Streja D
Curr Opin Investig Drugs; 2004 Mar; 5(3):306-12. PubMed ID: 15083597
[TBL] [Abstract][Full Text] [Related]
18. Lipid management in Type 1 diabetes.
Pachaiappan KJ; Patel V; Morrissey J; Gadsby R
Diabet Med; 2006 Mar; 23 Suppl 1():11-4. PubMed ID: 16483259
[No Abstract] [Full Text] [Related]
19. Achieving lipid goals in Europe: how large is the treatment gap?
Schwandt P; Brady AJ
Expert Rev Cardiovasc Ther; 2004 May; 2(3):431-49. PubMed ID: 15151488
[TBL] [Abstract][Full Text] [Related]
20. Are we ready for a statin on our toast?
DeSilvey DL
Am J Geriatr Cardiol; 2006; 15(6):392-3. PubMed ID: 17086036
[No Abstract] [Full Text] [Related]
[Next] [New Search]
